News

Remap Consulting welcomes Hannah Lorquet to the team!

We are delighted to announce the appointment of Hannah Lorquet as a Consultant at Remap Consulting bringing with her a strong background in Market Access.

Hannah studied at the University of Nottingham and has over 12 years experience in both the Pharmaceutical Industry and Market Access Consultancy sectors.

Outside of work, when not looking after her two young children, Hannah loves playing tennis.

We are sure Hannah is going to settle in really well!

By |2019-08-21T15:40:46+01:00August 21st, 2019|Careers, News|0 Comments

Our abstract has been accepted as a podium presentation at ISPOR Copenhagen 2019

Is market access for oncology treatments easier in England than for non-oncology treatments? An analysis of NICE single technology appraisals from 2017-2019

OBJECTIVES : The National Institute of Health and Care Excellence (NICE) undertakes clinical and cost-effectiveness assessments of pharmaceutical products. Products assessed by NICE can be either recommended, recommended with restrictions (i.e. optimised) or not recommended. Oncology products may also be recommended for use within the cancer drugs fund (CDF). This study compares the outcomes for oncology and non-oncology appraisals conducted by NICE.

METHODS : NICE single technology appraisals (STAs) published between January 2017 and January 2019 were identified. For each appraisal, outcomes of draft appraisal consultation documents (ACDs) and final appraisal determinations (FADs) were extracted. Outcomes of oncology and non-oncology appraisals were then analysed.

RESULTS : A total of 98 appraisals were identified, of which 66% and 34% were for oncology and non-oncology indications, respectively. ACDs were published […]

By |2019-08-09T11:50:02+01:00August 13th, 2019|News, Publications|0 Comments

Remap Consulting are delighted to have had a podium presentation and four poster abstracts accepted for ISPOR Copenhagen

Our podium presentation:

Is market access for oncology treatments easier in England than for non-oncology treatments? An analysis of NICE single technology appraisals from 2017-2019

Will be presented on 4th November during breakout session 2 at 14:15

Abstracts:

Abstract 1: Are patient access schemes and commercial access agreements essential for NICE to recommend access? A comparison of oncology and non-oncology appraisals

Abstract 2: Pricing and market access launch excellence: What are the key challenges facing companies today?

Abstract 3: Are acute therapies and curative drugs more affordable than chronic treatments in rare diseases? An analysis of the top 20 most expensive drugs in the US

Abstract 4: Was the evidence base for Yescarta and Kymriah sufficient to justify their cost and secure patient access across 5 markets?

By |2019-08-09T10:58:40+01:00August 2nd, 2019|News|0 Comments

Current and future evolution of commercial patient access scheme arrangements in England

In England, to gain a positive recommendation for use within the NHS from the National Institute of Health and Care Excellence (NICE), pharmaceutical products must demonstrate cost-effectiveness. In order to achieve this, manufacturers often agree financial agreements with NHS England. Indeed, the use of such agreements to improve the cost effectiveness of products has increased substantially in recent years.

In line with the 2014 Pharmaceutical Pricing Regulation Schemes (PPRS), financial agreements in England have typically been in the form of patient access schemes (PAS). In most cases, PAS involve simple discounts, with the manufacturer providing a confidential discount to the list price of the product. These agreements have often been favoured due to their relative ease of arrangement and transactability. However, PAS may also involve complex arrangements such as the provision of free stock, dose caps or (less frequently) payments by results. These have generally been less favoured due […]

By |2019-08-09T10:59:57+01:00July 31st, 2019|News|0 Comments

Remap Consulting are delighted to introduce their next training workshop

Join us on the 21st November at the Courtyard Marriott Brussels Hotel for an informative workshop on ‘Fundamentals of real world evidence for optimising market access’.

Click on the picture below for further information and to register.

Training advert

By |2019-08-09T11:12:23+01:00July 24th, 2019|News|0 Comments

Charlie is attending the Westminster Health Forum Keynote Seminar tomorrow

The topic is ‘Biosimilars in the NHS – commissioning, development and engagement with clinicians and patients’.

If you are in the area, or indeed attending the same event, please stop by to say hello and see how we can help you with your Pharmaceutical Pricing and Market Access requirements in Biosimilars.

picture of Charlie Hewitt

By |2019-08-09T11:13:45+01:00July 15th, 2019|News|0 Comments

Remap Consulting are hiring!

Remap Consulting is a specialist pharmaceutical pricing and market access consultancy. We are growing, and looking for a full time Analyst to join our successful team. If you have an entrepreneurial spirit and a passion for pharmaceutical pricing and market access, enjoy working in a diverse team with no two days the same, then we’d love to hear from you.

Click on the picture for further information:

Analyst vacancy

By |2019-08-09T11:15:24+01:00July 10th, 2019|Careers, News|0 Comments